|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-12-7
|
|
pubmed:abstractText |
Herein we describe a series of potent and selective PPARgamma agonists with moderate PPARalpha affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:AgejasJavierJ,
pubmed-author:AltCharles ACA,
pubmed-author:ArdeckyRobertR,
pubmed-author:BriereDaniel ADA,
pubmed-author:BrooksDawn ADA,
pubmed-author:BrozinickJoseph TJT,
pubmed-author:Dolores Martín-OrtegaMaríaM,
pubmed-author:FerrittoRafaelR,
pubmed-author:FraserJames DJD,
pubmed-author:GonzálezRosarioR,
pubmed-author:HawkinsEricE,
pubmed-author:López de UraldeBeatrizB,
pubmed-author:LamasCarlosC,
pubmed-author:MartínJosé AJA,
pubmed-author:MisenerElizabeth AEA,
pubmed-author:Montrose-RafizadehChahrzadC,
pubmed-author:ParraFranciscoF,
pubmed-author:PrietoLourdesL,
pubmed-author:Reifel-MillerAnneA,
pubmed-author:RhodesGary AGA,
pubmed-author:RizzoJohn RJR,
pubmed-author:RobeyRoger LRL,
pubmed-author:RojoIsabelI,
pubmed-author:TorradoAliciaA,
pubmed-author:WarshawskyAlan MAM,
pubmed-author:WendelSamuel RSR,
pubmed-author:ZhangTony YTY
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
51-5
|
|
pubmed:meshHeading |
pubmed-meshheading:15582409-Animals,
pubmed-meshheading:15582409-Blood Glucose,
pubmed-meshheading:15582409-Cinnamates,
pubmed-meshheading:15582409-Diabetes Mellitus, Type 2,
pubmed-meshheading:15582409-Disease Models, Animal,
pubmed-meshheading:15582409-Dose-Response Relationship, Drug,
pubmed-meshheading:15582409-Peroxisome Proliferator-Activated Receptors,
pubmed-meshheading:15582409-Rats,
pubmed-meshheading:15582409-Rats, Zucker,
pubmed-meshheading:15582409-Structure-Activity Relationship,
pubmed-meshheading:15582409-Triglycerides
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
|
|
pubmed:affiliation |
Lilly Research Laboratories, Division of Eli Lilly & Company, Lilly S.A., Alcobendas 28108, Madrid, Spain. martin_jose_alfredo@lilly.com
|
|
pubmed:publicationType |
Journal Article
|
